Elevated serum level of type-2 cytokine and low IL-17 in first episode psychosis and schizophrenia in relapse

Borovcanin, M.; Jovanović, Ivan; Radosavljević, Gordana; Dejanovic, Slavica Djukic; Banković, Dragić; Arsenijević, Nebojša; Lukic, Miodrag L.

doi:10.1016/j.jpsychires.2012.08.016

Cited by 126 publications

(87 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has been shown that the type-1 response is blunted and that the type-2 response is heightened in schizophrenia (14,21), and our results indicate reduced type-17 and anti-inflammatory response through production of the TGF-β regulatory cytokine (22)(23)(24).…”

Section: Cytokines As Biomarkers In Schizophreniasupporting

confidence: 66%

“…We also found that the levels of TGF-β and IL-23 were increased in all psychotic patients and that the IL-6 serum levels decreased only after antipsychotic treatment (22)(23)(24). At the onset of illness, TGF-β most likely plays an immunosuppressive role, and IL-23 may have pathogenic effects unrelated to IL-17.…”

Section: Tgf-β In Schizophreniamentioning

confidence: 58%

“…Data from the literature also indicate that the serum levels of TGF-β are significantly increased in patients with schizophrenia in relapse and first-episode psychosis compared with a control group (21,49). A meta-analysis of plasma cytokine alterations suggested that TGF-β is the state marker for acute exacerbation of schizophrenia (21) and that it can be a valuable marker for psychosis (22). Recent studies have questioned these findings and did not find a difference in the TGF-β serum levels between patients with schizophrenia and controls (50).…”

Section: Tgf-β In Schizophreniamentioning

confidence: 99%

See 2 more Smart Citations

Possible Role of TGF – B Pathways in Schizophrenia / Moguća Uloga TTGF - B Signalnih Puteva U Shizofreniji

Borovcanin

Jovanović

Dejanovic

et al. 2016

Serbian Journal of Experimental and Clinical Research

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Cytokines As Biomarkers In Schizophreniasupporting

confidence: 66%

Section: Tgf-β In Schizophreniamentioning

confidence: 58%

Section: Tgf-β In Schizophreniamentioning

confidence: 99%

See 1 more Smart Citation

Possible Role of TGF – B Pathways in Schizophrenia / Moguća Uloga TTGF - B Signalnih Puteva U Shizofreniji

Borovcanin

Jovanović

Dejanovic

et al. 2016

Serbian Journal of Experimental and Clinical Research

Self Cite

View full text Add to dashboard Cite

show abstract

“…Moreover, a previous study found increased activation of T-helper-17 cells in patients with recent onset SCZ [30]. Therefore, an existing imbalance of the IL-17 pathway, may be implicated in the etiology of SCZ [18,31].…”

Section: Immunoinflammatory Biomarkersmentioning

confidence: 93%

“…IL-17 induces the production of factors implicated in the recruitment of monocytes and neutrophils [29]. The levels of very few of those factors were found to be positively or negatively correlated with positive, general and total scores on the Positive and Negative Syndrome Scale (PANSS) in most studies conducted so far [18,21,31]. Moreover, a previous study found increased activation of T-helper-17 cells in patients with recent onset SCZ [30].…”

Section: Immunoinflammatory Biomarkersmentioning

confidence: 99%

Biomarkers and schizophrenia: a qualitative review

Silva¹,

Pinto²

2017

IJCNMH

View full text Add to dashboard Cite

Schizophrenia (SCZ) is a psychiatric disorder with a broad spectrum of biological and clinical manifestations of yet not completely clear pathophysiological mechanisms. Several lines of evidence have been supporting the idea that immunoinflammatory, oxidative, hormonal and cellular dysfunctions are implicated on the biomolecular basis of SCZ. However, accurate diagnosis and selection of appropriate treatments remains challenging as a result of the scarcity of objective tests. Furthermore, there is a compelling need to find biomarkers that could predict drug response and tailor pharmacological treatment, particularly in drug-naïve first episode psychosis (FEP). Hence, numerous technologies have been employed in order to search for SCZ biological markers, but evidence relating them to treatment efficacy is lacking. In this regard, some preliminary data suggest promising results. The current review provides information on: (1) potential biomarkers associated with biological disturbances and (2) biological markers associated with treatment response.

show abstract

Possible involvement of Interleukin‐17A in the deterioration of prepulse inhibition on acoustic startle response in mice

Wakabayashi

2023

Neuropsychopharm Rep

View full text Add to dashboard Cite

AimProinflammatory cytokines such as interleukin‐6 (IL‐6) and IL‐17A have been implicated in the pathophysiology of schizophrenia which often shows sensorimotor gating abnormalities. This study aimed to examine whether a proinflammatory cytokine, IL‐17A, induces impairment in sensorimotor gating in mice. We also examined whether IL‐17A administration affects GSK3α/β protein level or phosphorylation in the striatum.MethodsRecombinant mouse IL‐17A (low‐dose: 0.5 ng/mL and high‐dose: 50 ng/mL with 10 μL/g mouse body weight, respectively) or vehicle was intraperitoneally administered into C57BL/6 male mice 10 times in 3 weeks (sub‐chronic administration). Prepulse inhibition test using acoustic startle stimulus was conducted 4 weeks after the final IL‐17A administration. We evaluated the effect of IL‐17A administration on protein level or phosphorylation of GSK3α/β in the striatum by using Western blot analysis.ResultsAdministration of IL‐17A induced significant PPI deterioration. Low‐dose of IL‐17A administration significantly decreased both GSK3α (Ser21) and GSK3β (Ser9) phosphorylation in mouse striatum. There was no significant alteration of GSK3α/β protein levels except for GSK3α in low‐dose IL‐17A administration group.ConclusionWe demonstrated for the first time that sub‐chronic IL‐17A administration induced PPI disruption and that IL‐17A administration resulted in decreased phosphorylation of GSKα/β at the striatum. These results suggest that IL‐17A could be a target molecule in the prevention and treatment of sensorimotor gating abnormalities observed in schizophrenia.

show abstract

Elevated serum level of type-2 cytokine and low IL-17 in first episode psychosis and schizophrenia in relapse

Cited by 126 publications

References 42 publications

Possible Role of TGF – B Pathways in Schizophrenia / Moguća Uloga TTGF - B Signalnih Puteva U Shizofreniji

Possible Role of TGF – B Pathways in Schizophrenia / Moguća Uloga TTGF - B Signalnih Puteva U Shizofreniji

Biomarkers and schizophrenia: a qualitative review

Possible involvement of Interleukin‐17A in the deterioration of prepulse inhibition on acoustic startle response in mice

Contact Info

Product

Resources

About